诚意药业(603811) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥158,062,744.48, representing a decrease of 4.70% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥37,576,202.24, down 5.47% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥37,221,530.94, a decrease of 5.62% compared to the previous year[5] - The basic earnings per share for Q3 2022 was ¥0.16, reflecting a decline of 5.88% year-on-year[6] - Total operating revenue for the first three quarters of 2022 was CNY 476,221,538.79, a decrease of 9.1% compared to CNY 523,732,179.68 in the same period of 2021[19] - Net profit for the third quarter of 2022 was CNY 102,486,877.63, a decline of 13.5% from CNY 118,457,818.07 in the same quarter of 2021[20] - Basic and diluted earnings per share for the third quarter of 2022 were both CNY 0.44, down from CNY 0.51 in the same quarter of 2021[21] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥1,596,670,427.54, an increase of 20.73% from the end of the previous year[6] - The company's total assets as of September 30, 2022, amount to CNY 1,596,670,427.54, an increase from CNY 1,322,493,361.66 at the end of 2021[16] - Current assets total CNY 404,722,929.22, up from CNY 287,797,305.90 in the previous year[16] - Total liabilities have increased to CNY 564,438,463.48 from CNY 323,616,586.46[17] - The company has a total equity of CNY 1,032,231,964.06 as of September 30, 2022[17] - The short-term borrowings amount to CNY 101,355,636.10, an increase from CNY 86,362,967.36[16] - The long-term borrowings have significantly increased to CNY 263,592,900.95 from CNY 59,627,951.45[17] Cash Flow - The cash flow generated from operating activities for the year-to-date was ¥106,729,566.50, showing an increase of 16.37%[6] - Cash flow from operating activities for the first three quarters of 2022 was CNY 106,729,566.50, an increase of 16.4% compared to CNY 91,717,153.63 in the same period of 2021[24] - The company received CNY 485,055,716.42 in cash from operating activities during the first three quarters of 2022, compared to CNY 515,579,877.56 in the same period of 2021[24] - Cash inflow from financing activities totaled $390,265,237.08, compared to $83,107,452.81 in the previous year, marking a significant increase[25] - Net cash flow from financing activities was $194,780,298.44, a turnaround from a negative cash flow of -$29,707,148.75 in the same quarter last year[25] - Cash and cash equivalents at the end of the period reached $195,984,125.00, up from $99,047,594.61 year-over-year, indicating a strong liquidity position[25] - The net increase in cash and cash equivalents for the quarter was $114,583,665.66, compared to $26,787,024.31 in the same quarter last year, showcasing improved cash generation[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,754[12] - The largest shareholder, Yan Yiyi, holds 55,137,200 shares, representing 23.58% of total shares[12] Investment and Expenses - The company is investing in a marine biopharmaceutical manufacturing project, which has led to increased capital expenditures[10] - Research and development expenses for the first three quarters of 2022 were CNY 35,003,808.66, an increase of 18.2% from CNY 29,531,472.54 in the previous year[19] - The company reported a total investment income of CNY 35,106,827.77 for the first three quarters of 2022, up from CNY 27,366,321.15 in the same period of 2021[19] Foreign Exchange and Other Impacts - The company experienced a foreign exchange loss of CNY 3,547,000.00 in the third quarter of 2022[20] - The impact of exchange rate fluctuations on cash and cash equivalents was a positive $392,960.59, contrasting with a negative impact of -$448,695.05 last year[25]